; (B) may have sources of health care coverage in addition to coverage under such title; or (C) pay for prescription drugs with cash. (3) Any other purposes specified by the Secretary. (b) Elements of model practices The model practices described in subsection (a)— (1) may include strategies for assisting States in allowing the medical director or pharmacy director (or designees of such a director) of managed care organizations or pharmaceutical benefit managers to access information with respect to all covered individuals served by such managed care organizations or pharmaceutical benefit managers to access as a single data set, in an electronic format; and (2) shall include any appropriate beneficiary protections and privacy guidelines. (c) Consultation In developing model practices under this section, the Secretary shall consult with the National Association of Medicaid Directors, managed care entities (as defined in section 1932(a)(1)(B) of the Social Security Act) with contracts with States pursuant to section 1903(m) of such Act, pharmaceutical benefit managers, physicians and other health care providers, beneficiary advocates, and individuals with expertise in health care technology related to prescription drug monitoring programs and electronic health records. 5. Report by Comptroller General Not later than October 1, 2020, the Comptroller General of the United States shall issue a report examining the operation of prescription drug monitoring programs administered by States, including data security and access standards used by such programs.